DA
DCPH

Denali Advisors’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Denali Advisors’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-7,900
Closed -$104K – 424
2022
Q2 		$104K Hold
7,900
– – 0.05% 172
2022
Q1 		$73K Buy
7,900
+2,000
+34% +$17K 0.03% 217
2021
Q4 		$58K Buy
+5,900
New +$111K 0.02% 236

Other funds holding DCPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Denali Advisors's DCPH Position: Q3 2022 in Review

Denali Advisors sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q3 2022, closing a stake of 7,900 shares — an estimated $104K sold.

Denali Advisors first reported a position in DCPH in Q4 2021 and held it in 3 quarters. The position peaked at $104K in Q2 2022. 150 funds tracked by Wall St. Rank hold DCPH as of Q3 2022.

  • Denali Advisors reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Denali Advisors sold 7,900 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $104K.
  • Denali Advisors first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • Denali Advisors's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $104K in Q2 2022.
  • 150 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Denali Advisors's 13F filing for Q3 2022, filed 25 Oct 2022.